Ann: Quarterly Activities Report, page-71

tbh I'm not sure if we read the same quarterly.

If anything, FFX seems to be thinking a lot harder about how to maximise shareholder value in developing Goulamina than many people thought. A Downstream Scoping Study has been commissioned to consider the economics of refining the spodumene into lithium sulphate and/or lithium hydroxide, thus capturing more value for FFX shareholders (pages 9 and 10 of the quarterly ICYMI).